All In Biotech

Drug Trial Radar · NCT05934214

EXploring Immune-related Adverse Events of Immune checkpoinT Inhibitors Using VigiBase, the WHO Pharmacovigilance Database

Immune-related Adverse Events From Immune Checkpoint Inhibitor Characterization Using VigiBase, the WHO Pharmacovigilance Database: An Exploration of Adverse Event Patterns and Signal Detection.

Last checked: Nov 20, 2026Latest source record: Mar 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

141,630

Actual

Start

Jan 1, 2023

Primary completion

Dec 31, 2023

Study completion Feb 29, 2024

Sponsor

Lead sponsor
Groupe Hospitalier Pitie-SalpetriereAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Institut Curie
First posted
Jul 6, 2023

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an observational, retrospective pharmacovigilance study based on reports registered and transmitted in VigiBase®, the WHO's international database. This study includes all reports identified as exposure to an ICI and suspect of inducing adverse drug reaction. The aim of the study is to characterize immune-related adverse reactions associated with immune-checkpoint inhibitors, particularly their time-to-onset, co-occurence, factors associate with their over-report and fatality.

Conditions

  • Cancer
  • Immune-related Adverse Event
  • Immune Checkpoint Inhibitor-Related Myocarditis

Interventions

  • Immune checkpoint inhibitorDrug

    Reports associated with an an Immune checkpoint inhibitor with a status of "Suspect" or "Interacting" ICI will include the following list of FDA-apporved ICIs: nivolumab, pembrolizumab, cemiplimab, dostarlimab, durvalumab, atezolizumab, avelumab, ipilimumab, tremelimumab, relatlimab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Factors associated with an increased rate of fatality among reports with an immune-related adverse event (irAE).Time frame: any report prior to january 2023

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM.

    Paris, France

  • CIC Paris-Est / Institut Curie

    Paris, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.